title: Assessment of early therapy response with 18F-FLT PET in glioblastoma multiforme.
abstract: Early therapy response assessment in glioblastoma multiforme remains a challenge. Evaluation by MRI relies on changes in tumor contrast enhancement or size, which are usually not visible at early therapy response assessment times. In addition, MRI may not be reliable for early therapy response assessment if only molecular changes have occurred. PET with F-FLT, a tracer associated with cellular proliferation, has been proposed as a potential method of early therapy response assessment and is an area of active research. We present a case where early response assessment with F-FLT PET was associated with a favorable 1-year follow-up outcome.
authors.affiliation: From the Departments of *Radiology, and †Bioengineering, University of Pittsburgh, Pittsburgh, PA; ‡Department of Nuclear Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey; and §Division of Hematology/Oncology, Departments of Neurology and Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA.
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Oborski
authors.forename: Emre
authors.initials: E
authors.lastname: Demirci
authors.forename: Charles M
authors.initials: CM
authors.lastname: Laymon
authors.forename: Frank S
authors.initials: FS
authors.lastname: Lieberman
authors.forename: James M
authors.initials: JM
authors.lastname: Mountz
mesh_terms: D001932:Brain Neoplasms / Q000000981:diagnostic imaging* / Q000601:surgery; D015224:Dideoxynucleosides; D005260:Female; D005909:Glioblastoma / Q000000981:diagnostic imaging* / Q000601:surgery; D006801:Humans; D008875:Middle Aged; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D016896:Treatment Outcome
chemical_list: D015224:Dideoxynucleosides; D019275:Radiopharmaceuticals; C002854:alovudine